logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery preparing to do something 'very different' in drug development

Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.

They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1.

It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

Quick facts: C4X Discovery Holdings PLC

Price: 17.75 GBX

AIM:C4XD
Market: AIM
Market Cap: £21.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 on the up as airline stocks surge higher

Headlines from the Proactive UK newsroom. The FTSE 100 index rose again as airline stocks surged higher. British Airways owner IAG led the way climbing 11% in the morning while the index jumped 71 to 6,412. AstraZenecasays it will soon be able to supply two billion doses of a potential...

on 5/6/20

2 min read